Large cell carcinoma of the lung medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung. Chemotherapy may be required upon histological subtype of large cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for large cell carcinoma of the lung is [[neoadjuvant chemotherapy]] or [[adjuvant chemotherapy]], followed or preceded by surgical resection. There is no consensus on treatment in patients with large cell lung neuroendocrine carcinoma. Commonly used chemotherapeutic agents, include: [[cisplatin]], [[erlotinib]], [[paclitaxel]], [[docetaxel]], [[carboplatin]], [[etoposide]] or [[vinorelbine]].<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="wikip">Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref><ref name="pmid4042022">{{cite journal |vauthors=Ishii K, Ishii N, Shigenobu K, Kasuya Y |title=Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy |journal=Can. J. Physiol. Pharmacol. |volume=63 |issue=7 |pages=898–9 |year=1985 |pmid=4042022 |doi= |url=}}</ref> | Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung. Chemotherapy may be required upon histological subtype of large cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for large cell carcinoma of the lung is [[neoadjuvant chemotherapy]] or [[adjuvant chemotherapy]], followed or preceded by surgical resection. There is no consensus on treatment in patients with large cell lung neuroendocrine carcinoma. Commonly used chemotherapeutic agents, include: [[cisplatin]], [[erlotinib]], [[paclitaxel]], [[docetaxel]], [[carboplatin]], [[etoposide]] or [[vinorelbine]].<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="wikip">Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref><ref name="pmid4042022">{{cite journal |vauthors=Ishii K, Ishii N, Shigenobu K, Kasuya Y |title=Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy |journal=Can. J. Physiol. Pharmacol. |volume=63 |issue=7 |pages=898–9 |year=1985 |pmid=4042022 |doi= |url=}}</ref> | ||
== | ==Medical Therapy== | ||
*Initial chemotherapy for patients with large cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging. | *Initial chemotherapy for patients with large cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging. | ||
| Line 33: | Line 33: | ||
* To see more information about the chemotherapeutic regimens in non-small cell lung cancer click [[Non small cell lung cancer chemotherapy#Chemotherapeutic Regimens|here]] | * To see more information about the chemotherapeutic regimens in non-small cell lung cancer click [[Non small cell lung cancer chemotherapy#Chemotherapeutic Regimens|here]] | ||
==Complications | ==Complications== | ||
*Medical therapy complications for large cell carcinoma of the lung will depend on the chemotherapeutic agent. | *Medical therapy complications for large cell carcinoma of the lung will depend on the chemotherapeutic agent. | ||
*Common chemotherapy complications, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref> | *Common chemotherapy complications, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref> | ||
Revision as of 20:19, 9 March 2016
|
Large Cell Carcinoma of the Lung Microchapters |
|
Differentiating Large Cell Carcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Large cell carcinoma of the lung medical therapy On the Web |
|
American Roentgen Ray Society Images of Large cell carcinoma of the lung medical therapy |
|
Large cell carcinoma of the lung medical therapy in the news |
|
Directions to Hospitals Treating Large cell carcinoma of the lung |
|
Risk calculators and risk factors for Large cell carcinoma of the lung medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung. Chemotherapy may be required upon histological subtype of large cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for large cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. There is no consensus on treatment in patients with large cell lung neuroendocrine carcinoma. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.[1][2][3]
Medical Therapy
- Initial chemotherapy for patients with large cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
- Chemotherapy for patients with large cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
- Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung
- Erlotinib is the first-line treatment for patients with large cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
- Chemotherapy treatments for large cell carcinoma of the lung, include:[1]
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of large cell carcinoma of the lung
- Platinum-based chemotherapy consists of four to six cycles
- Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
- To see more information about mangnagment approach for non-small cell lung cancer click here
- To see more information about the chemotherapeutic regimens in non-small cell lung cancer click here
Complications
- Medical therapy complications for large cell carcinoma of the lung will depend on the chemotherapeutic agent.
- Common chemotherapy complications, include:[1]
- Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapeutic agent complications, include:
- Side effects symptoms of chemotherapeutic agents, include:
References
- ↑ 1.0 1.1 1.2 Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
- ↑ Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330
- ↑ Ishii K, Ishii N, Shigenobu K, Kasuya Y (1985). "Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy". Can. J. Physiol. Pharmacol. 63 (7): 898–9. PMID 4042022.